Objective: To probe into the effects of clopidogrel treatment on short-term efficacy

relief time of symptoms and inflammatory factors in children with intravenous immunoglobulin-resistant Kawasaki disease. Methods: A total of 72 children with intravenous immunoglobulin-resistant Kawasaki disease were extracted to be divided into the observation group and the control group

with 36 cases in each group. The control group was treated with aspirin combined with dipyridamole-assisted gamma globulin

while the observation group received clopidogrel based on the control group. The short-term efficacy

relief time of symptoms

white blood cell count (WBC)

platelet count (PLT)

C-reactive protein (CRP)

procalcitonin (PCT)

interleukin-6 (IL-6)

and tumor necrosis factor α (TNF-α)

high mobility group protein B1 (HMGB1)

and macrophage migration inhibitory factor (MIF) before and after treatment in two groups were compared. The incidence of coronary artery dilatation

coronary aneurysm and adverse drug reactions in two groups were analyzed. Results: There was no significant difference in the total effective rate between two groups (P>0.05). The duration of fever

disappearance time of enlargement of cervical lymph nodes

disappearance time of diffuse mucosal congestion and remission time of trunk erythema in the observation group were significantly shorter than those in the control group (P<0.05). The levels of WBC

PLT

CRP

PCT

IL-6

TNF-α

HMGB1 and MIF in the observation group after treatment were significantly lower than those in the control group (P<0.05). The incidence of coronary artery dilation in the observation group was 8.33%

significantly lower than that in the control group (P<0.05). There was no significant difference in the incidence of adverse drug reactions between two groups (P>0.05). Conclusion: Clopidogrel in adjuvant treatment of children with intravenous immunoglobulin-resistant Kawasaki disease can improve the short-term efficacy

shorten the relief time of symptoms and

reduce the inflammatory response and coronary artery injury with higher safety.